PL2714010T3 - Kompozycja farmaceutyczna do miejscowego stosowania oparta na semifluorowanych alkanach - Google Patents

Kompozycja farmaceutyczna do miejscowego stosowania oparta na semifluorowanych alkanach

Info

Publication number
PL2714010T3
PL2714010T3 PL12723683T PL12723683T PL2714010T3 PL 2714010 T3 PL2714010 T3 PL 2714010T3 PL 12723683 T PL12723683 T PL 12723683T PL 12723683 T PL12723683 T PL 12723683T PL 2714010 T3 PL2714010 T3 PL 2714010T3
Authority
PL
Poland
Prior art keywords
pharmaceutical composition
composition based
topical pharmaceutical
semifluorinated alkanes
semifluorinated
Prior art date
Application number
PL12723683T
Other languages
English (en)
Inventor
Bernhard Günther
Bastian Theisinger
Sonja Theisinger
Dieter Scherer
Original Assignee
Novaliq Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novaliq Gmbh filed Critical Novaliq Gmbh
Publication of PL2714010T3 publication Critical patent/PL2714010T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07Retinol compounds, e.g. vitamin A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/12Keratolytics, e.g. wart or anti-corn preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL12723683T 2011-05-25 2012-05-24 Kompozycja farmaceutyczna do miejscowego stosowania oparta na semifluorowanych alkanach PL2714010T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11167552 2011-05-25
EP11167732 2011-05-26
EP12723683.4A EP2714010B1 (en) 2011-05-25 2012-05-24 Topical pharmaceutical composition based on semifluorinated alkanes

Publications (1)

Publication Number Publication Date
PL2714010T3 true PL2714010T3 (pl) 2017-08-31

Family

ID=46168482

Family Applications (2)

Application Number Title Priority Date Filing Date
PL17154837T PL3192501T3 (pl) 2011-05-25 2012-05-24 Kompozycja farmaceutyczna do miejscowego stosowania oparta na semifluorowanych alkanach
PL12723683T PL2714010T3 (pl) 2011-05-25 2012-05-24 Kompozycja farmaceutyczna do miejscowego stosowania oparta na semifluorowanych alkanach

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL17154837T PL3192501T3 (pl) 2011-05-25 2012-05-24 Kompozycja farmaceutyczna do miejscowego stosowania oparta na semifluorowanych alkanach

Country Status (13)

Country Link
US (4) US10130707B2 (pl)
EP (3) EP2714010B1 (pl)
JP (3) JP6039145B2 (pl)
KR (2) KR20170122282A (pl)
CN (4) CN107397718A (pl)
AU (3) AU2012260787B2 (pl)
CA (1) CA2834855C (pl)
DK (2) DK2714010T3 (pl)
ES (3) ES2962524T3 (pl)
HK (1) HK1247116A1 (pl)
PL (2) PL3192501T3 (pl)
PT (2) PT2714010T (pl)
WO (1) WO2012160179A2 (pl)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8911494B2 (en) 2009-05-04 2014-12-16 Valtech Cardio, Ltd. Deployment techniques for annuloplasty ring
EP2506777B1 (en) 2009-12-02 2020-11-25 Valtech Cardio, Ltd. Combination of spool assembly coupled to a helical anchor and delivery tool for implantation thereof
KR101656121B1 (ko) 2010-03-17 2016-09-08 노바리크 게엠베하 안압 증가를 치료하기 위한 약학 조성물
EP3441045B1 (en) 2010-06-07 2020-07-29 Valtech Cardio, Ltd. Apparatus to draw first and second portions of tissue toward each other
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
AU2012260788B2 (en) 2011-05-25 2017-01-19 Dermaliq Therapeutics, Inc. Pharmaceutical composition for administration to nails
KR20170122282A (ko) 2011-05-25 2017-11-03 노바리크 게엠베하 부분불소화된 알칸에 기초된 국소 제약학적 조성물
GB201120593D0 (en) * 2011-11-29 2012-01-11 Gsi Group Ltd Gas bearing spindles and gas bearing assemblies for gas bearing spindles
JP6084987B2 (ja) 2012-01-23 2017-02-22 ノバリック ゲーエムベーハー セミフッ素化アルカンに基づく安定化タンパク質組成物
AU2013314370B2 (en) 2012-09-12 2017-11-30 Novaliq Gmbh Compositions comprising mixtures of semifluorinated alkanes
AU2013314303B2 (en) 2012-09-12 2018-01-18 Novaliq Gmbh Semifluorinated alkane compositions
EP2948134B1 (en) 2013-01-24 2020-03-04 Palvella Therapeutics, Inc. Compositions for transdermal delivery of mtor inhibitors
PT3024484T (pt) 2013-07-23 2018-10-24 Novaliq Gmbh Composições de anticorpo estabilizadas
US9522189B2 (en) * 2013-12-20 2016-12-20 Johnson & Johnson Consumer Inc. Topical gel compositions including poly(monostearoyl glycerol-co-succinate) polymer and methods for enhancing the topical application of a benefit agent
EP2944324A1 (de) 2014-05-13 2015-11-18 LTS LOHMANN Therapie-Systeme AG Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen
ES2743502T3 (es) 2015-09-30 2020-02-19 Novaliq Gmbh Compuestos semifluorados y sus composiciones
DK3722274T3 (da) 2015-09-30 2023-09-11 Novaliq Gmbh 2-perfluorbutylpentan til oftalmisk indgivelse
CN105663027B (zh) * 2016-04-01 2018-12-18 中国人民解放军***武汉总医院 西罗莫司外用制剂、其制备方法及用途
WO2017220625A1 (en) 2016-06-23 2017-12-28 Novaliq Gmbh Topical administration method
PL3515420T3 (pl) 2016-09-22 2024-04-08 Novaliq Gmbh Kompozycje farmaceutyczne do zastosowania w terapii zapalenia brzegów powiek
EP3515467B1 (en) 2016-09-23 2023-11-29 Novaliq GmbH Ophthalmic compositions comprising ciclosporin
US10751295B2 (en) * 2016-11-09 2020-08-25 Specialty Drug and Device, LLC Compositions and methods for the removal of ear wax
KR102602890B1 (ko) 2016-12-22 2023-11-15 노바리크 게엠베하 안구내 염증성 눈 질환 치료용 타크로리무스를 함유하는 조성물
IL302385B2 (en) 2017-01-06 2024-06-01 Palvella Therapeutics Inc Non-aqueous preparations of mTOR inhibitors and methods of use
WO2018193093A1 (en) * 2017-04-21 2018-10-25 Novaliq Gmbh Iodine compositions
CN110650734A (zh) 2017-05-12 2020-01-03 诺瓦利克有限责任公司 治疗与隐形眼镜有关病症的包含半氟化烷烃的药物组合物
WO2018215638A1 (en) 2017-05-26 2018-11-29 Novaliq Gmbh Pharmaceutical compositions comprising azithromycin
JP2020535156A (ja) 2017-09-27 2020-12-03 ノバリック ゲーエムベーハー 眼疾患の治療に使用するためのラタノプロストを含む眼科用組成物
US11896559B2 (en) 2017-10-04 2024-02-13 Novaliq Gmbh Opthalmic compositions comprising F6H8
AU2019228119A1 (en) 2018-03-02 2020-09-10 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
WO2020010073A1 (en) 2018-07-02 2020-01-09 Palvella Therapeutics, Inc. ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE
CA3111870C (en) * 2018-09-27 2022-04-12 Novaliq Gmbh Topical sunscreen formulation
EP3856124A1 (en) * 2018-09-27 2021-08-04 Novaliq GmbH Lipid barrier repair
AU2019358249B2 (en) 2018-10-12 2024-02-22 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
EP3861857A1 (en) * 2020-02-07 2021-08-11 Novaliq GmbH Antiparasitic compositions

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10022A (en) 1853-09-13 Lard-lamp
US2616927A (en) 1950-05-12 1952-11-04 Minnesota Mining & Mfg Fluorocarbon tertiary amines
JPS5721312A (en) 1980-07-12 1982-02-04 Green Cross Corp:The Breathable ointment
US4452818A (en) 1982-03-19 1984-06-05 Haidt Sterling J Extraocular method of treating the eye with liquid perfluorocarbons
US5077036A (en) 1986-01-14 1991-12-31 Alliance Pharmaceutical Corp. Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid
JPH0764702B2 (ja) 1986-04-23 1995-07-12 鐘紡株式会社 多相乳化型化粧料
JPS6452722A (en) 1987-05-01 1989-02-28 Anjierini Pharmaceut Inc Ophthalmic composition
JP3046346B2 (ja) 1990-03-12 2000-05-29 昭和電工株式会社 外用剤基剤又は補助剤とそれを含有する人又は動物の外用剤
US6458376B1 (en) 1990-09-27 2002-10-01 Allergan, Inc. Nonaqueous fluorinated drug delivery suspensions
US5518731A (en) 1990-09-27 1996-05-21 Allergan, Inc. Nonaqueous fluorinated drug delivery vehicle suspensions
US5152997A (en) 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
US5326566A (en) 1991-05-17 1994-07-05 Bristol-Myers Squibb Company Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
FR2679150A1 (fr) 1991-07-17 1993-01-22 Atta Preparations comprenant un fluorocarbure ou compose hautement fluore et un compose organique lipophile-fluorophile, et leurs utilisations.
US5336175A (en) 1992-10-29 1994-08-09 Mames Robert N Method for the treatment of retinal detachments
DE4405627A1 (de) 1994-02-22 1995-08-24 Hoechst Ag Fluorkohlenwasserstoffe enthaltende Ölemulsionen
FR2720943B1 (fr) 1994-06-09 1996-08-23 Applic Transferts Technolo Emulsions inverses stables à forte concentration en composé(s) fluoré(s) et leur utilisation pour l'administration pulmonaire de médicaments et pour la fabrication d'émulsions multiples.
US6294563B1 (en) 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
US5696164A (en) 1994-12-22 1997-12-09 Johnson & Johnson Consumer Products, Inc. Antifungal treatment of nails
US5667809A (en) 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
US5874481A (en) * 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
DE19536504C2 (de) 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
US5874469A (en) 1996-01-05 1999-02-23 Alcon Laboratories, Inc. Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs
RU2111738C1 (ru) 1996-06-24 1998-05-27 Акционерное общество "НИЗАР" Средство для усиления солнцезащитной активности фотозащитных агентов
FR2752161B1 (fr) 1996-08-07 1998-09-25 Atta Emulsions multiples de type hydrocarbure-dans-eau-dans- fluorocarbone pour le transport de substances medicamenteuses hydrophiles et/ou lipophiles
US5863560A (en) 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
IN184589B (pl) 1996-10-16 2000-09-09 Alza Corp
DE19709704C2 (de) 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
US5980936A (en) 1997-08-07 1999-11-09 Alliance Pharmaceutical Corp. Multiple emulsions comprising a hydrophobic continuous phase
US5851544A (en) * 1997-12-18 1998-12-22 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic skin or hair care compositions containing fluorocarbons infused with carbon dioxide
US5981607A (en) 1998-01-20 1999-11-09 Allergan Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers
DK0983037T3 (da) 1998-02-09 2003-09-01 Macrochem Corp Fungicid neglelak
DE19861012A1 (de) 1998-03-18 1999-09-30 Pharm Pur Gmbh Behandlungsmittel für die Ophthalmologie
AU759641B2 (en) 1998-08-19 2003-04-17 Skyepharma Canada Inc. Injectable aqueous dispersions of propofol
US6140374A (en) 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
US6159977A (en) 1998-11-16 2000-12-12 Astan, Inc. Therapeutic anti-fungal nail preparation
HUP0200202A3 (en) 1999-02-08 2009-08-28 Alza Corp Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
EP1124416A1 (en) 1999-03-15 2001-08-22 John Claude Krusz Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages
US6177477B1 (en) 1999-03-24 2001-01-23 American Home Products Corporation Propofol formulation containing TRIS
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
DE19926890C1 (de) 1999-06-12 2000-07-27 Pharm Pur Gmbh Verwendung eines hochfluorierten oligomeren Alkans in der Ophthalmologie
DE19938668B4 (de) 1999-08-14 2006-01-26 Bausch & Lomb Inc. Tränenersatzmittel
US6528086B2 (en) 1999-09-28 2003-03-04 Zars, Inc. Methods and apparatus for drug delivery involving phase changing formulations
JP2001158734A (ja) 1999-12-02 2001-06-12 Lion Corp 眼科用組成物及びソフトコンタクトレンズに対する吸着抑制方法
US20030018044A1 (en) 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
DE10024413A1 (de) 2000-05-19 2001-12-06 Mika Pharma Gmbh Pharmazeutische und/oder kosmetische Zubereitung
DE10042412B4 (de) 2000-08-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Abgabe von Venlafaxin, und seine Verwendung
US6399087B1 (en) 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
CA2446060A1 (en) 2001-05-07 2002-11-14 Corium International Compositions and delivery systems for administration of a local anesthetic agent
RU2302857C2 (ru) 2001-09-04 2007-07-20 Тромсдорф ГмбХ унд Ко.КГ Арцнаймиттель Способ и пластырь для профилактики и/или лечения дисфункции и/или нарушения роста ногтей
JP2005523252A (ja) 2002-01-26 2005-08-04 マイクロ サイエンス テック コーポレーション リミテッド 牧丹皮抽出物を有効成分として含む組成物
EP2422768B1 (en) 2003-08-25 2015-04-15 Foamix Pharmaceuticals Ltd. Penetrating pharmaceutical foam
US20050079210A1 (en) 2003-10-09 2005-04-14 Gupta Shyam K. Liposomal delivery system for topical pharmaceutical, cosmeceutical, and cosmetic ingredients
EP1670433B1 (en) 2003-10-10 2011-11-23 Antares Pharma IPL AG Transdermal pharmaceutical formulation for minimizing skin residues
WO2005051305A2 (en) 2003-11-19 2005-06-09 Barnes-Jewish Hospital Enhanced drug delivery
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
US20080019926A1 (en) 2004-04-19 2008-01-24 Marie-Pierre Krafft Lung Surfactant Supplements
CA2569726A1 (en) 2004-06-08 2005-12-29 Ocularis Pharma, Inc. Hydrophobic ophthalmic compositions and methods of use
JP2008505177A (ja) 2004-07-01 2008-02-21 ザ・シェペンズ・アイ・リサーチ・インスティテュート・インコーポレーテッド 目の障害および状態を治療するための組成物および方法
US7740875B2 (en) 2004-10-08 2010-06-22 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US20060078580A1 (en) 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
EP1688161A1 (en) 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
GB0511499D0 (en) * 2005-06-06 2005-07-13 Medpharm Ltd Topical ungual formulations
JP2009503059A (ja) 2005-08-05 2009-01-29 ブハラット セルムズ アンド ヴァクシンズ リミテッド 防腐効果を有する静脈プロポフォールエマルジョン組成物
FR2892023B1 (fr) 2005-10-14 2009-09-25 Galderma Sa Composition pharmaceutique a base d'amorolfine et d'agent filmogene hydrosoluble pour application ungueale et peri-ungueale
DE102005050431A1 (de) 2005-10-21 2007-04-26 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreicherung lipophiler und/oder wenig hautpermeabler Wirkstoffe
DE102005055811A1 (de) * 2005-11-23 2007-05-31 Novaliq Gmbh Verwendung einer Zusammensetzung zur Konservierung von Organen und Gliedmaßen
TWI376239B (en) 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
CA2658646A1 (en) 2006-07-25 2008-01-31 Osmotica Corp. Ophthalmic solutions
EP2068828A2 (en) 2006-09-29 2009-06-17 SurModics, Inc. Biodegradable ocular implants and methods for treating ocular conditions
DE102007055046A1 (de) 2007-11-19 2009-05-28 Fluoron Gmbh Infusionslösung
US20090136430A1 (en) * 2007-11-27 2009-05-28 Dugger Harry A Antihistamine/Corticosteroid preparations for the treatment of atopic dermatitis
EP2110126B9 (de) 2008-04-18 2012-09-19 Novaliq GmbH Inhalative und instillative Verwendung von semifluorierten Alkanen als Wirkstoffträger im intrapulmonalen Bereich
US20100189765A1 (en) 2008-11-26 2010-07-29 Erickson Signe R Implantable ocular drug delivery device and methods
JP4642905B2 (ja) 2009-01-22 2011-03-02 株式会社資生堂 乳化化粧料
US8501800B2 (en) 2009-03-05 2013-08-06 Insite Vision Incorporated Controlled-release ophthalmic vehicles
IT1393419B1 (it) 2009-03-19 2012-04-20 Medivis S R L Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6.
WO2010146536A1 (en) 2009-06-18 2010-12-23 Koninklijke Philips Electronics N.V. Suspension of particles with drug
JP5736635B2 (ja) 2009-06-25 2015-06-17 ライオン株式会社 ドライアイ治療剤
KR101702157B1 (ko) 2009-06-25 2017-02-13 라이온 가부시키가이샤 안과용 조성물
SI2387391T1 (sl) 2009-07-24 2017-04-26 Mika Pharma Gesellschaft Fuer Die Entwicklung Und Vermarktung Pharmazeutischer Produkte Mbh Postopek za pripravo tekočega sestavka, ki se nanaša na kožo v obliki pene, in sestavka, ki se lahko nanaša topično
EP2332525A1 (en) 2009-11-23 2011-06-15 Novaliq GmbH Pharmaceutical composition comprising propofol
EP2335735A1 (en) 2009-12-14 2011-06-22 Novaliq GmbH Pharmaceutical composition for treatment of dry eye syndrome
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
KR101656121B1 (ko) 2010-03-17 2016-09-08 노바리크 게엠베하 안압 증가를 치료하기 위한 약학 조성물
DE102010022567A1 (de) 2010-06-02 2011-12-08 Fluoron Gmbh Zubereitung
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
PL3202421T3 (pl) 2011-01-04 2018-10-31 Novaliq Gmbh Emulsje o/w zawierające semifluorowane alkany
US20120219640A1 (en) 2011-02-25 2012-08-30 Wright Kenneth W Anti-infective solution for athlete's foot
AU2012260788B2 (en) 2011-05-25 2017-01-19 Dermaliq Therapeutics, Inc. Pharmaceutical composition for administration to nails
KR20170122282A (ko) 2011-05-25 2017-11-03 노바리크 게엠베하 부분불소화된 알칸에 기초된 국소 제약학적 조성물
US8758826B2 (en) 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods
JP6084987B2 (ja) 2012-01-23 2017-02-22 ノバリック ゲーエムベーハー セミフッ素化アルカンに基づく安定化タンパク質組成物
AU2013314370B2 (en) 2012-09-12 2017-11-30 Novaliq Gmbh Compositions comprising mixtures of semifluorinated alkanes
AU2013314303B2 (en) 2012-09-12 2018-01-18 Novaliq Gmbh Semifluorinated alkane compositions
EP2783703A1 (en) 2013-03-25 2014-10-01 B. Braun Melsungen AG Semifluorocarbon compound containing contrast agent
PT3024484T (pt) 2013-07-23 2018-10-24 Novaliq Gmbh Composições de anticorpo estabilizadas
EP2944324A1 (de) 2014-05-13 2015-11-18 LTS LOHMANN Therapie-Systeme AG Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen
DK3722274T3 (da) 2015-09-30 2023-09-11 Novaliq Gmbh 2-perfluorbutylpentan til oftalmisk indgivelse
ES2743502T3 (es) 2015-09-30 2020-02-19 Novaliq Gmbh Compuestos semifluorados y sus composiciones
CN106176937A (zh) 2016-08-24 2016-12-07 刘艺鹏 湿疹、痤疮软膏
WO2018193093A1 (en) 2017-04-21 2018-10-25 Novaliq Gmbh Iodine compositions
CA3111870C (en) 2018-09-27 2022-04-12 Novaliq Gmbh Topical sunscreen formulation
US20220362382A1 (en) 2019-08-09 2022-11-17 Dermaliq Therapeutics, Inc Topical composition comprising a prostaglandin analogue
EP3861857A1 (en) 2020-02-07 2021-08-11 Novaliq GmbH Antiparasitic compositions

Also Published As

Publication number Publication date
CN103596554A (zh) 2014-02-19
US20210100904A1 (en) 2021-04-08
JP6901421B2 (ja) 2021-07-14
ES2962524T3 (es) 2024-03-19
PT3192501T (pt) 2020-07-31
ES2808051T3 (es) 2021-02-25
JP2014517841A (ja) 2014-07-24
CA2834855C (en) 2020-12-29
CN109260193A (zh) 2019-01-25
AU2017200622B2 (en) 2018-05-17
CN107397718A (zh) 2017-11-28
PT2714010T (pt) 2017-05-05
EP3311802C0 (en) 2023-11-01
EP2714010A2 (en) 2014-04-09
HK1247116A1 (zh) 2018-09-21
EP2714010B1 (en) 2017-03-01
JP2017075147A (ja) 2017-04-20
EP3311802A1 (en) 2018-04-25
JP6306126B2 (ja) 2018-04-04
EP3192501A2 (en) 2017-07-19
KR101790388B1 (ko) 2017-10-25
CA2834855A1 (en) 2012-11-29
JP6039145B2 (ja) 2016-12-07
PL3192501T3 (pl) 2020-11-02
US11844836B2 (en) 2023-12-19
DK3192501T3 (da) 2020-08-03
WO2012160179A3 (en) 2013-01-17
AU2017200622A1 (en) 2017-02-23
JP2018123138A (ja) 2018-08-09
CN108283623A (zh) 2018-07-17
EP3192501A3 (en) 2017-11-08
EP3192501B1 (en) 2020-05-13
ES2623233T3 (es) 2017-07-10
US10130707B2 (en) 2018-11-20
KR20140040751A (ko) 2014-04-03
EP3311802B1 (en) 2023-11-01
WO2012160179A2 (en) 2012-11-29
US10813999B2 (en) 2020-10-27
US20140100180A1 (en) 2014-04-10
US20220218828A1 (en) 2022-07-14
AU2018206812B2 (en) 2020-02-20
AU2018206812A1 (en) 2018-08-09
AU2012260787B2 (en) 2017-02-02
DK2714010T3 (en) 2017-06-12
US20180021434A1 (en) 2018-01-25
KR20170122282A (ko) 2017-11-03

Similar Documents

Publication Publication Date Title
HK1247116A1 (zh) 基於半氟化烷烴類的外用藥物組合物
AP3864A (en) Pharmaceutical composition
PT3202421T (pt) Emulsões de o/a que compreendem alcanos semifluorados
EP2729131A4 (en) TOPICAL COMPOSITIONS
EP2706987B8 (en) Pharmaceutical compositions
IL230861A (en) A rapidly dissolving pharmaceutical composition
HK1212898A1 (zh) 酮洛芬的局部組合物
HK1202448A1 (en) Topical formulation for administering a compound
GB201118232D0 (en) Pharmaceutical composition
EP2938325B8 (en) Diclofenac composition
HK1189158A1 (en) Pharmaceutical composition
EP2769718A4 (en) MEDICINAL COMPOSITION
EP2685993A4 (en) PHARMACEUTICAL COMPOSITIONS AND TOPICAL USE THEREOF
EP2727593A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING NICORANDIL
EP2711010A4 (en) PHARMACEUTICAL COMPOSITION
HUP1100444A2 (en) Pharmaceutical composition
HK1198912A1 (en) Topical pharmaceutical compositions comprising acyclovir
EP2851074A4 (en) ANALGETIC PHARMACEUTICAL COMPOSITION
HUP1100445A2 (en) Pharmaceutical composition
GB201110027D0 (en) Topical formulation
GB201110030D0 (en) Topical formulation
AU2011905393A0 (en) Pharmaceutical Composition
ZA201309537B (en) Pharmaceutical composition comprising fexofedine
IL220512A0 (en) Compositions for topical administration
AU2012904295A0 (en) Pharmaceutical composition